- Home
- PLBC vs NLSP Comparison
PLBC vs NLSP Comparison
Compare PLBC & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLBC
- NLSP
- Stock Information
- Founded
- PLBC 1980
- NLSP 2015
- Country
- PLBC United States
- NLSP Switzerland
- Employees
- PLBC N/A
- NLSP N/A
- Industry
- PLBC Finance Companies
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- PLBC Finance
- NLSP Health Care
- Exchange
- PLBC Nasdaq
- NLSP Nasdaq
- Market Cap
- PLBC 236.7M
- NLSP 12.4M
- IPO Year
- PLBC 2005
- NLSP 2021
- Fundamental
- Price
- PLBC $45.89
- NLSP $2.10
- Analyst Decision
- PLBC Buy
- NLSP
- Analyst Count
- PLBC 4
- NLSP 0
- Target Price
- PLBC $55.75
- NLSP N/A
- AVG Volume (30 Days)
- PLBC 14.5K
- NLSP 275.3K
- Earning Date
- PLBC 07-21-2025
- NLSP 07-22-2025
- Dividend Yield
- PLBC 2.62%
- NLSP N/A
- EPS Growth
- PLBC 3.33
- NLSP N/A
- EPS
- PLBC 4.95
- NLSP N/A
- Revenue
- PLBC $84,001,000.00
- NLSP N/A
- Revenue This Year
- PLBC $19.95
- NLSP N/A
- Revenue Next Year
- PLBC $22.19
- NLSP N/A
- P/E Ratio
- PLBC $9.26
- NLSP N/A
- Revenue Growth
- PLBC 9.14
- NLSP N/A
- 52 Week Low
- PLBC $35.16
- NLSP $1.30
- 52 Week High
- PLBC $51.33
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- PLBC 55.23
- NLSP 46.61
- Support Level
- PLBC $45.40
- NLSP $2.20
- Resistance Level
- PLBC $46.34
- NLSP $3.08
- Average True Range (ATR)
- PLBC 1.24
- NLSP 0.25
- MACD
- PLBC 0.13
- NLSP -0.06
- Stochastic Oscillator
- PLBC 52.66
- NLSP 8.40
About PLBC Plumas Bancorp
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.